BEDFORD, Mass., May 8, 2012 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced that their Strategic Alliance Cross-Distribution agreement with Beckman Coulter (BCI) will terminate June 22, 2012, after more than twenty successful years. Beginning June 23, 2012, IL will initiate direct sales, service, support and marketing to end-user customers in the U.S. and Canada, for their own Hemostasis product line, including the HemosIL® line of reagents, ACL TOP® Family of Hemostasis Testing Systems, ACL ELITE®/ELITE PRO analyzers and other ACL® systems.
The transition will allow IL to apply the same direct business model employed in their Critical Care business, for over fifty years, to their Hemostasis product line. Closer proximity to the customer means IL can quickly respond to changing needs, continuously improve the quality of their products and services, expedite innovation to Hemostasis labs, and reduce complexity of operations. R&D and Manufacturing for all of IL's Hemostasis analyzers and reagents, along with their world-class Hemostasis expertise, reside at their headquarters in Massachusetts and New York.
"IL has achieved significant growth in Hemostasis, culminating in the attainment of the number one market share position worldwide, thanks to our focus on quality and innovation," said Ramon Benet, CEO at IL. "Now is the ideal time for us to apply our expertise, resources, and world-class service organization to working directly with our Hemostasis customers in North America, and focus on ensuring a smooth transition for our customers."
Up to and including June 22, 2012, Hemostasis customers and customer organizations will continue to contact BCI directly for service, support and products. IL Customer Service is available now, at 1-800-678-0710, option 2, or at ILresponse@ilww.com to address any question
|SOURCE Instrumentation Laboratory|
Copyright©2010 PR Newswire.
All rights reserved